If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Prostate Cancer, Decision Resources is offering an exclusive analyst call entitled Turbulent Times in the Prostate Cancer Drug Market – What Are the Commercial Implications of Recent Events? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us learn how you can purchase this Pharmacor advisory service and attend the analyst call. Within the last month, major news concerning emerging therapies for metastatic castrate-resistant prostate cancer (MCRPC) has been reported. This presentation will focus on these events, including the key clinical results announced during the recent European Society for Medical Oncology (ESMO) annual conference. Johnson & Johnson’s abiraterone has been shown to improve median overall survival by 3.9 months in MCRPC, an impressive achievement in this heavily pre-treated patient population. This data will drive uptake in first-, second- and third-line treatment of MCRPC. Other recent developments include the failure of two agents in separate pivotal Phase III clinical trials, highlighting the significant challenges for emerging therapies entering this highly lucrative market. AstraZeneca’s zibotentan failed to significantly improve overall survival in the asymptomatic/minimally symptomatic metastatic castrate-resistant setting, and Pfizer’s Sutent failed in combination with prednisone in the chemotherapy pretreated setting. In addition, two new pivotal Phase III trials for Takeda’s TAK-700 are scheduled to begin in the asymptomatic/minimally symptomatic and chemotherapy pretreated settings. TAK-700 has the potential to compete with abiraterone based on its mechanism of action. Additionally, the results of a new pivotal Phase III clinical trial could expand the commercial potential for Medivation/Astellas’s MDV-3100 into asymptomatic/minimally symptomatic MCRPC by building on the ongoing Phase III trial in the chemotherapy pretreated setting. Lastly, a new pivotal Phase III trial is beginning in October for Teva Pharmaceuticals/OncoGenex’s custirsen in combination with chemotherapy for first-line MCRPC. This high-interest novel agent has potential to improve survival and is building on the ongoing Phase III trial in the chemotherapy pretreated setting which is evaluating pain palliation as the primary end point. This 15-minute analyst call, presented by Analyst Andrew Merron, Ph.D., will answer the following questions:
Dr. Merron will conduct a live Q & A session after the presentation. Registration Turbulent Times in the Prostate Cancer Drug Market – What Are the Commercial Implications of Recent Events? October 20, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Andrew Merron, Ph.D., is a senior oncology analyst at Decision Resources. Dr Merron’s research interests and areas of expertise cover hematological malignancies (including lymphoma, leukemia and myeloma) and prostate cancer. Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses. Prior to obtaining his Ph.D., he earned his B.Sc. in biochemistry from the University of Bath.